California Northstate University, USA
Xiaodong Feng received his Ph.D. training in Cellular and Molecular Physiology and PharmD training specialized in pharmacy education and clinical pharmacy practice. He started biomedical research career eighteen years ago as a postdoctoral fellow in the Wound Healing Center, School of Medicine at Stony Brook. After three years of fellowship, he continued research and teaching as an Assistant Professor in Department of Dermatology, State University of New York at Stony Brook for another 4 years. Currently he is teaching at California Northstate University College of Pharmacy as Associate Professor of Clinical Sciences. He has about twenty years of clinical and biomedical research experience in cancer, wound healing, and cardiovascular diseases. He also practices as a clinical pharmacist in a top 100 hospital.
Background: The Food and Drug Administration Adverse Event Reporting System (FAERS) represents one of the most successful digital tools of media landscape sponsored by the government. Using the FAERS, clinicians have uncovered many critical drug safety issues that create significantly impact on patient care and patient support. However, the role of the FAERS in cancer control and prevention in the changing media landscape and new information ecology remains largely unknown. Methods: Using the FAERS public database, the adverse event reports (ADRs) associated with widely used anti-diabetic drugs of dipeptidyl peptidase 4 (DPP 4) inhibitors were generated and evaluated. Standardized pharmacovigilance tools were applied to detect the signal for cancer risk. Based on the AERs from 2007 to 2011, reported cancer adverse events associated with DPP 4 inhibitors were analyzed. Results: Among 12618 ADRs associated with sitagliptin from 2007 to 2011, there were 223 cases of cancer. There was a significant correlation between the cancer proportional reporting ratio and the time (R = 0.796, P<0.001). Pancreatic cancer, leukemia, lung cancer, breast cancer and bladder cancer were the top five most prevalent cancers reported. Pancreatic cancers accounted for 22% of all combined cancer adverse events. Pharmacovigilance assessment indicated that there was a significant association between pancreatic cancer and DPP 4 inhibitor treatment. Conclusion: There is a significant increase in cancer reports associated with DDP 4 inhibitor treatment. Considering the limitation of the FAERS, this study signals the potential cancer risk associated with DPP 4 inhibitor drugs. These findings may provide future directions for clinical studies of cancer control and prevention.